Geneos Therapeutics Secures $17 Million in Series A2 Financing to Advance Personalized Cancer Immunotherapy PlatformPRNewsWire • 03/24/22
Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim Presents at Oppenheimer's 32nd Annual Healthcare Conference (Transcript)Seeking Alpha • 03/15/22
Lab Study Shows Inovio's COVID-19 Vaccine Candidate Weaker Against Omicron VariantBenzinga • 03/02/22
Inovio Pharmaceuticals, Inc. (INO) CEO Dr. Joseph Kim on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/02/22
Inovio Pharmaceuticals (INO) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/02/22
INOVIO to Report Fourth Quarter and Year-End 2021 Financial Results on March 1, 2022PRNewsWire • 02/15/22
Down 21.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)Zacks Investment Research • 01/11/22
Is A Rise Imminent For Inovio Pharmaceuticals Stock After A Large 17% Fall In A MonthForbes • 12/17/21
INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18PRNewsWire • 12/14/21